TY - JOUR AU - Woolf, A. D. AU - Pfleger, B. PY - 2003 DA - 2003// TI - Burden of major musculoskeletal conditions JO - Bull World Health Organ VL - 81 ID - Woolf2003 ER - TY - JOUR AU - Reginster, J. Y. PY - 2002 DA - 2002// TI - The prevalence and burden of arthritis JO - Rheumatology VL - 41 UR - https://doi.org/10.1093/rheumatology/41.suppl_1.3 DO - 10.1093/rheumatology/41.suppl_1.3 ID - Reginster2002 ER - TY - JOUR AU - Jordan, K. M. AU - Arden, N. K. AU - Doherty, M. AU - Bannwarth, B. AU - Bijlsma, J. W. AU - Dieppe, P. AU - Gunther, K. AU - Hauselmann, H. AU - Herrero-Beaumont, G. AU - Kaklamanis, P. AU - Lohmander, S. AU - Leeb, B. AU - Lequesne, M. AU - Mazieres, B. AU - Martín-Mola, E. AU - Pavelka, K. AU - Pendleton, A. AU - Punzi, L. AU - Serni, U. AU - Swoboda, B. AU - Verbruggen, G. AU - Zimmerman-Gorska, I. AU - Dougados, M. PY - 2003 DA - 2003// TI - EULAR Recommendations 2003: an evidence based approach to the management of knee osteoarthritis: Report of a Task Force of the Standing Committee forInternational Clinical Studies Including Therapeutic Trials (ESCISIT) JO - Ann Rheum Dis VL - 62 UR - https://doi.org/10.1136/ard.2003.011742 DO - 10.1136/ard.2003.011742 ID - Jordan2003 ER - TY - STD TI - Murray CJL, Lopez AD, Eds: The global burden of disease. A comprehensive assessment of mortality and disability from diseases, injuries, and risk factors in 1990 and projected to 2020. 1996, Cambridge, MA; Harvard School of Public Health on behalf of the World Health Organization and The World Bank ID - ref4 ER - TY - JOUR PY - 2000 DA - 2000// TI - Recommendations for the medical management of osteoarthritis of the hip and knee: 2000 update. American College of Rheumatology Subcommittee on Osteoarthritis Guidelines JO - Arthritis Rheum VL - 43 UR - https://doi.org/3.0.CO;2-P DO - 3.0.CO;2-P ID - ref5 ER - TY - JOUR AU - Dougados, M. PY - 2001 DA - 2001// TI - The role of anti-inflammatory drugs in the treatment of osteoarthritis: a European viewpoint JO - Clin Exp Rheumatol VL - 19 ID - Dougados2001 ER - TY - JOUR AU - Moskowitz, R. W. PY - 2001 DA - 2001// TI - The role of anti-inflammatory drugs in the treatment of osteoarthritis: a United States viewpoint JO - Clin Exp Rheumatol VL - 19 ID - Moskowitz2001 ER - TY - JOUR AU - Langman, M. J. AU - Weil, J. AU - Wainwright, P. AU - Lawson, D. H. AU - Rawlins, M. D. AU - Logan, R. F. AU - Murphy, M. AU - Vessey, M. P. AU - Colin-Jones, D. G. PY - 1994 DA - 1994// TI - Risk of bleeding peptic ulcer associated with individual non-steroidal anti-inflammatory drugs JO - Lancet VL - 343 UR - https://doi.org/10.1016/S0140-6736(94)90185-6 DO - 10.1016/S0140-6736(94)90185-6 ID - Langman1994 ER - TY - JOUR AU - Wolfe, M. M. AU - Lichtenstein, D. R. AU - Singh, G. PY - 1999 DA - 1999// TI - Gastrointestinal toxicity of nonsteroidal anti-inflammatory drugs JO - N Engl J Med VL - 340 UR - https://doi.org/10.1056/NEJM199906173402407 DO - 10.1056/NEJM199906173402407 ID - Wolfe1999 ER - TY - JOUR AU - Hawkey, C. J. PY - 1999 DA - 1999// TI - COX-2 inhibitors JO - Lancet VL - 353 UR - https://doi.org/10.1016/S0140-6736(98)12154-2 DO - 10.1016/S0140-6736(98)12154-2 ID - Hawkey1999 ER - TY - JOUR AU - Detora, L. M. AU - Krupa, D. AU - Bolognese, J. AU - Sperling, R. S. AU - Ehrich, E. W. PY - 2001 DA - 2001// TI - Rofecoxib shows consistent efficacy in osteoarthritis clinical trials, regardless of specific patient demographic and disease factors JO - J Rheumatol VL - 28 ID - Detora2001 ER - TY - JOUR AU - Edwards, J. E. AU - McQuay, H. J. AU - Moore, R. A. PY - 2004 DA - 2004// TI - Efficacy and safety of valdecoxib for treatment of osteoarthritis and rheumatoid arthritis: systematic review of randomised controlled trials JO - Pain VL - 111 UR - https://doi.org/10.1016/j.pain.2004.07.004 DO - 10.1016/j.pain.2004.07.004 ID - Edwards2004 ER - TY - JOUR AU - Pincus, T. AU - Koch, G. AU - Lei, H. AU - Mangal, B. AU - Sokka, T. AU - Moskowitz, R. AU - Wolfe, F. AU - Gibofsky, A. AU - Simon, L. AU - Zlotnick, S. AU - Fort, J. G. PY - 2004 DA - 2004// TI - Patient Preference for Placebo, Acetaminophen (paracetamol) or Celecoxib Efficacy Studies (PACES): two randomised, double blind, placebo controlled, crossover clinical trials in patients with knee or hip osteoarthritis JO - Ann Rheum Dis VL - 63 UR - https://doi.org/10.1136/ard.2003.020313 DO - 10.1136/ard.2003.020313 ID - Pincus2004 ER - TY - JOUR AU - Berenbaum, F. AU - Grifka, J. AU - Brown, J. P. AU - Zacher, J. AU - Moore, A. AU - Krammer, G. AU - Dutta, D. AU - Sloan, V. S. PY - 2005 DA - 2005// TI - Efficacy of lumiracoxib in osteoarthritis: a review of nine studies JO - J Int Med Res VL - 33 UR - https://doi.org/10.1177/147323000503300102 DO - 10.1177/147323000503300102 ID - Berenbaum2005 ER - TY - JOUR AU - Fleischmann, R. AU - Sheldon, E. AU - Maldonado-Cocco, J. AU - Dutta, D. AU - Yu, S. AU - Sloan, V. S. PY - 2006 DA - 2006// TI - Lumiracoxib is effective in the treatment of osteoarthritis of the knee: a prospective randomized 13-week study versus placebo and celecoxib JO - Clin Rheumatol VL - 25 UR - https://doi.org/10.1007/s10067-005-1126-5 DO - 10.1007/s10067-005-1126-5 ID - Fleischmann2006 ER - TY - JOUR AU - Lehmann, R. AU - Brzosko, M. AU - Kopsa, P. AU - Nischik, R. AU - Kreiss, A. AU - Thurston, H. AU - Litschig, S. AU - Sloan, V. S. PY - 2005 DA - 2005// TI - Efficacy and tolerability of lumiracoxib 100 mg once daily in knee osteoarthritis: a 13-week, randomized, double-blind study vs. placebo and celecoxib JO - Curr Med Res Opin VL - 21 UR - https://doi.org/10.1185/030079905X38196 DO - 10.1185/030079905X38196 ID - Lehmann2005 ER - TY - JOUR AU - Sheldon, E. AU - Beaulieu, A. AU - Paster, Z. AU - Dutta, D. AU - Yu, S. AU - Sloan, V. S. PY - 2005 DA - 2005// TI - Efficacy and tolerability of lumiracoxib in the treatment of osteoarthritis of the knee: a 13-week, randomized, double-blind comparison with celecoxib and placebo JO - Clin Ther VL - 27 UR - https://doi.org/10.1016/j.clinthera.2005.01.002 DO - 10.1016/j.clinthera.2005.01.002 ID - Sheldon2005 ER - TY - JOUR AU - Tannenbaum, H. AU - Berenbaum, F. AU - Reginster, J. Y. AU - Zacher, J. AU - Robinson, J. AU - Poor, G. AU - Bliddal, H. AU - Uebelhart, D. AU - Adami, S. AU - Navarro, F. AU - Lee, A. AU - Moore, A. AU - Gimona, A. PY - 2004 DA - 2004// TI - Lumiracoxib is effective in the treatment of osteoarthritis of the knee: a 13 week, randomised, double blind study versus placebo and celecoxib JO - Ann Rheum Dis VL - 63 UR - https://doi.org/10.1136/ard.2003.015974 DO - 10.1136/ard.2003.015974 ID - Tannenbaum2004 ER - TY - JOUR AU - Fricke, J. AU - Davis, N. AU - Yu, V. PY - 2006 DA - 2006// TI - An evaluation of the efficacy of lumiracoxib 400 mg, celecoxib 400 mg or placebo for treating pain following dental surgery JO - Reg Anesth Pain Med VL - 30 ID - Fricke2006 ER - TY - STD TI - Kyle C, Zachariah J, Kasangra M, Andrews C, Ellis G, Kinch H: Lumiracoxib 400 mg once daily is comparable to naproxen 500 mg twice daily for treatment of acute muscular pain following soft tissue injury. Ann Rheum Dis. 2006, 241-(Abstract THU0415), Suppl II ID - ref20 ER - TY - CHAP AU - Gitton, X. AU - Zhou, W. AU - Jayawardene, S. AU - Daniels, S. AU - Barton, S. AU - Matchaba, P. PY - 2006 DA - 2006// TI - Lumiracoxib 200 mg od is an effective and well-tolerated treatment for primary dysmenorrhoea BT - British Pain Society (BPS) Abstract Book ID - Gitton2006 ER - TY - JOUR AU - Willburger, R. E. AU - Mysler, E. AU - Derbot, J. AU - Jung, T. AU - Thurston, H. AU - Kreiss, A. AU - Litschig, S. AU - Krammer, G. AU - Tate, G. A. PY - 2007 DA - 2007// TI - Lumiracoxib 400 mg once daily is comparable to indomethacin 50 mg three times daily for the treatment of acute flares of gout JO - Rheumatology VL - 46 UR - https://doi.org/10.1093/rheumatology/kem090 DO - 10.1093/rheumatology/kem090 ID - Willburger2007 ER - TY - JOUR AU - Scholes, D. AU - Stergachis, A. AU - Penna, P. M. AU - Normand, E. H. AU - Hansten, P. D. PY - 1995 DA - 1995// TI - Nonsteroidal antiinflammatory drug discontinuation in patients with osteoarthritis JO - J Rheumatol VL - 22 ID - Scholes1995 ER - TY - JOUR PY - 1994 DA - 1994// TI - Collaborative overview of randomised trials of antiplatelet therapy-I. Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients JO - BMJ VL - 308 UR - https://doi.org/10.1136/bmj.308.6921.81 DO - 10.1136/bmj.308.6921.81 ID - ref24 ER - TY - JOUR AU - Wolfe, F. AU - Michaud, K. AU - Burke, T. A. AU - Zhao, S. Z. PY - 2004 DA - 2004// TI - Longer use of COX-2-specific inhibitors compared to nonspecific nonsteroidal antiinflammatory drugs: a longitudinal study of 3639 patients in community practice JO - J Rheumatol VL - 31 ID - Wolfe2004 ER - TY - JOUR AU - Farkouh, M. E. AU - Kirshner, H. AU - Harrington, R. A. AU - Ruland, S. AU - Verheugt, F. W. AU - Schnitzer, T. J. AU - Burmester, G. R. AU - Mysler, E. AU - Hochberg, M. C. AU - Doherty, M. AU - Ehrsam, E. AU - Gitton, X. AU - Krammer, G. AU - Mellein, B. AU - Gimona, A. AU - Matchaba, P. AU - Hawkey, C. J. AU - Chesebro, J. H. PY - 2004 DA - 2004// TI - Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), cardiovascular outcomes: randomised controlled trial JO - Lancet VL - 364 UR - https://doi.org/10.1016/S0140-6736(04)16894-3 DO - 10.1016/S0140-6736(04)16894-3 ID - Farkouh2004 ER - TY - JOUR AU - Matchaba, P. AU - Gitton, X. AU - Krammer, G. AU - Ehrsam, E. AU - Sloan, V. S. AU - Olson, M. AU - Mellein, B. AU - Hoexter, G. AU - Orloff, J. AU - Garaud, J. -. J. PY - 2005 DA - 2005// TI - Cardiovascular safety of lumiracoxib: a meta-analysis of all randomized controlled trials ≥1 week and up to 1 year in duration of patients with osteoarthritis and rheumatoid arthritis JO - Clin Ther VL - 27 UR - https://doi.org/10.1016/j.clinthera.2005.07.019 DO - 10.1016/j.clinthera.2005.07.019 ID - Matchaba2005 ER - TY - JOUR AU - Kearney, P. M. AU - Baigent, C. AU - Godwin, J. AU - Halls, H. AU - Emberson, J. R. AU - Patrono, C. PY - 2006 DA - 2006// TI - Do selective COX-2 inhibitors and traditional NSAIDs increase the risk of atherothrombosis? Meta-analysis of randomised trials JO - BMJ VL - 332 UR - https://doi.org/10.1136/bmj.332.7553.1302 DO - 10.1136/bmj.332.7553.1302 ID - Kearney2006 ER - TY - JOUR AU - McGettigan, P. AU - Henry, D. PY - 2006 DA - 2006// TI - Cardiovascular risk and inhibition of cyclooxygenase: a systematic review of the observational studies of selective and nonselective inhibitors of cyclooxygenase 2 JO - JAMA VL - 296 UR - https://doi.org/10.1001/jama.296.13.jrv60011 DO - 10.1001/jama.296.13.jrv60011 ID - McGettigan2006 ER - TY - STD TI - Whitehead A, Simmonds M, Mellein B, Friede T, Gitton X, Sallstig P: Blood pressure profile of lumiracoxib is similar to placebo in arthritis patients. Osteoarthritis Cartilage. 2006, S168-S169. 10.1016/S1063-4584(07)60757-2. (Abstract P309), Suppl 2 ID - ref30 ER - TY - STD TI - Farkouh ME, Verheugt FWA, Kirshner H, Ruland S, Sallstig P, Stricker K, Krammer G, Mellein B, Gitton X, Matchaba P, Chesebro JH: Lumiracoxib provides superior blood pressure profile compared to NSAIDs after 4 weeks of treatment. Arthritis Rheum. 2006, S678-(Abstract 1692), Suppl 1 ID - ref31 ER - TY - JOUR AU - Traversa, G. AU - Bianchi, C. AU - Da Cas, R. AU - Abraha, I. AU - Menniti-Ippolito, F. AU - Venegoni, M. PY - 2003 DA - 2003// TI - Cohort study of hepatotoxicity associated with nimesulide and other non-steroidal anti-inflammatory drugs JO - BMJ VL - 327 UR - https://doi.org/10.1136/bmj.327.7405.18 DO - 10.1136/bmj.327.7405.18 ID - Traversa2003 ER - TY - STD TI - Motrin prescribing information. [http://www.pfizer.com/pfizer/download/uspi_motrin.pdf] UR - http://www.pfizer.com/pfizer/download/uspi_motrin.pdf ID - ref33 ER - TY - STD TI - Naprosyn product information. [http://www.rocheusa.com/products/naprosyn/pi.pdf] UR - http://www.rocheusa.com/products/naprosyn/pi.pdf ID - ref34 ER - TY - JOUR AU - Silverstein, F. E. AU - Faich, G. AU - Goldstein, J. L. AU - Simon, L. S. AU - Pincus, T. AU - Whelton, A. AU - Makuch, R. AU - Eisen, G. AU - Agrawal, N. M. AU - Stenson, W. F. AU - Burr, A. M. AU - Zhao, W. W. AU - Kent, J. D. AU - Lefkowith, J. B. AU - Verburg, K. M. AU - Geis, G. S. PY - 2000 DA - 2000// TI - Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: A randomized controlled trial. Celecoxib Long-term Arthritis Safety Study JO - JAMA VL - 284 UR - https://doi.org/10.1001/jama.284.10.1247 DO - 10.1001/jama.284.10.1247 ID - Silverstein2000 ER - TY - JOUR AU - Rostom, A. AU - Goldkind, L. AU - Laine, L. PY - 2005 DA - 2005// TI - Nonsteroidal anti-inflammatory drugs and hepatic toxicity: a systematic review of randomized controlled trials in arthritis patients JO - Clin Gastroenterol Hepatol VL - 3 UR - https://doi.org/10.1016/S1542-3565(04)00777-3 DO - 10.1016/S1542-3565(04)00777-3 ID - Rostom2005 ER - TY - STD TI - Pavelka K, Zamani O, Alten R, Yu S, Litschig S, Sloan VS: Lumiracoxib is effective and well tolerated in the long-term treatment of knee osteoarthritis. Ann Rheum Dis. 2005, 353-(Abstract FRI0319), Suppl 3 ID - ref37 ER - TY - STD TI - The pre-publication history for this paper can be accessed here:http://www.biomedcentral.com/1471-2474/9/32/prepub UR - http://www.biomedcentral.com/1471-2474/9/32/prepub ID - ref38 ER -